FIELD: chemistry; biotechnology.
SUBSTANCE: invention relates to biochemistry, in particular to an isolated anti-CD112R antibody or a fragment thereof. Also disclosed is a composition containing said antibody; nucleic acid coding said antibody; host cell containing said antibody. Disclosed is a method for enhancing, increasing and/or maintaining an anti-tumour immune response in a subject using said antibody, a method for enhancing the activation of CD8 T cells or NK cells in a subject using said antibody, a method for enhancing the production of interferon gamma by CD8 T cells using said antibody, a method for enhancing cytotoxicity using said antibody, a method for enhancing CD226 and CD112 interactions in a subject using said antibody, a method for producing said antibody.
EFFECT: invention has the ability to effectively treat diseases expressing CD112.
40 cl, 19 dwg, 12 tbl, 17 ex
| Title | Year | Author | Number |
|---|---|---|---|
| C10orf54 ANTIBODIES AND USE THEREOF | 2015 |
|
RU2714232C2 |
| ADVANCED PROCOAGULANT ANTIBODIES | 2019 |
|
RU2810748C2 |
| ANTI-C10orf54 ANTIBODIES AND APPLICATIONS THEREOF | 2015 |
|
RU2819627C1 |
| ANTIBODIES AGAINST SIGNAL-REGULATORY ALPHA PROTEIN AND THEIR APPLICATION METHODS | 2017 |
|
RU2771964C2 |
| CD131-BINDING PROTEINS AND THEIR APPLICATIONS | 2016 |
|
RU2773927C2 |
| CD40 LIGAND THERAPEUTIC ANTIBODIES | 2018 |
|
RU2770209C2 |
| ANTIBODIES TO PD-1 AND THEIR APPLICATION | 2017 |
|
RU2761640C2 |
| ANTIBODIES AGAINST TNFRSF9 AND THEIR USE | 2019 |
|
RU2812200C2 |
| COMBINATIONS OF ANTIBODIES TO STAPHYLOCOCCUS AUREUS | 2019 |
|
RU2804815C2 |
| ANTI-PD-L1 AND IL-2 CYTOKINES | 2017 |
|
RU2769282C2 |
